Our Mission

Joe has more than 35 years’ experience in the field of process monitoring and control instrumentation, with a primary focus on the Life Sciences industry for the past 25 years. Joe has held sales and sales management roles with Pall Life Sciences, optek-Danulat, Mettler Toledo Process Analytics and was most recently the R&D Director for Thermo Fisher’s Bioprocess Equipment and Automation Group. Joe believes that successful product design, marketing and sales start with a deep understanding of the specific customer application being targeted.  Listening to end users’ challenges and understanding their process requirements are the foundational steps required to bring meaningful innovation to the marketplace.   

Key Qualifications and Experience: 

• BA in Engineering Sciences, Dartmouth College, Hanover, NH 
• Masters degree in Mechanical Engineering, Thayer School of Engineering, Hanover, NH 
• Multiple patents for process monitoring and control instrumentation 

John started his Life Sciences career with Genentech in 1983.  After working in several operational roles for Genentech, John accepted a position as a Field Service Engineer with Millipore.  In this role, John was responsible for installation, IQ/OQ and operator training for TFF systems in North America.  John went on to become a Manufacturing Supervisor for Celtrix and later served as Director of Commercial Manufacturing Operations for IDEC pharmaceuticals. In 2007, John made the transition from end user to supplier when he became a Senior Account Manager for Pall Life Sciences. When John left Pall, he founded Process Integration and served as Managing Director/Owner of the successful rep firm and channel partner. John and his business partner sold Process Integration in 2019 and he has recently completed his commitment to support the new ownership during the transition.

Key Qualifications and Experience: 

• U.S. Approval of Rituxan®. Area expert, primary contact and lead for Manufacturing Operations regarding the pre-approval and post approval FDA Regulatory Inspections.  
• European Approval of Mabthera®. Area expert, primary contact and lead for Manufacturing Operations with regards to the pre-approval and post approval European Regulatory Inspections 
• Commercial manufacture of Rituxan® for market launch 

In 1806, brothers Henry and Sealy Fourdrinier were granted a patent for a machine that could make a long continuous roll of paper.  If the brothers were to visit a paper mill today, more than 200 years later, they would no doubt recognize their creation in the modern, Fourdrinier-style paper machine.  The scale, the speed and the automation have certainly changed, but the core technology remains; remarkably unchanged after more than two centuries.  The paper industry’s stability provides a sharp contrast to the biotech industry, which has existed for less than 50 years, during which it has experienced constant evolution coupled with paradigm shifting innovation. 

The birth of the biotech industry is usually considered to be 1982, when the US Food and Drug Administration approved Humulin, Eli Lily's recombinant insulin made from Genentech's genetically modified bacteria. Much of the equipment used in the production of Humulin was essentially “repurposed” from the brewing industry and other industrial fermentation and separation processes. In contrast to the papermaking industry, if you were to patch those early biotech pioneers into a 2025 Teams meeting discussing antibody-drug conjugate linkers, they would likely be hard pressed to even place this conversation in the context of their own evolving bioprocess.  

Perfusion, cell and gene therapy, membrane chromatography, continuous processing, CRISPR, contract manufacturing, ADCs, digital twins, mRNA vaccines, machine learning…  The list of major innovations in the evolution of bioprocessing in a little over four decades is remarkable. Arguably, none of these changes has had a greater impact on the manufacturing process than the introduction of single-use technologies. 

The rate at which bioprocessors have adopted single-use technologies is unprecedented.  Understandably, many suppliers to the industry have been challenged to match the speed and flexibility of the end-users.  For suppliers, single-use processing changes nearly every facet of business.  From product requirements and supply chain needs to go-to-market strategies and pricing structures, both the playing field and the rules of the game have been changed. Single-Use Strategies was founded to help suppliers navigate the rapidly evolving single-use landscape.  With extensive industry experience on both sides of the supply chain, Single-Use Strategies is uniquely equipped to help suppliers succeed in the ever-changing world of single-use processing.